Generation of electrophysiologically functional cardiomyocytes from mouse induced pluripotent stem cells  by Wang, Hongran et al.
Stem Cell Research 16 (2016) 522–530
Contents lists available at ScienceDirect
Stem Cell Research
j ourna l homepage: www.e lsev ie r .com/ locate /scrGeneration of electrophysiologically functional cardiomyocytes from
mouse induced pluripotent stem cellsHongran Wang a, Yutao Xi b, Yi Zheng c, Xiaohong Wang d, Austin J. Cooney a,⁎
a Department of Pediatrics, Dell Pediatric Research Institute, University of Texas at Austin Dell Medical School, 1400 Barbara Jordan Blvd., Austin, TX 78723, USA
b Electrophysiology Research Laboratory, Texas Heart Institute, Houston, TX 77030, USA
c Department of Internal Medicine, University of Nevada School of Medicine, Reno, NV 89557, USA
d Stem Cell Center, Texas Heart Institute, Houston, TX 77030, USA⁎ Corresponding author.
E-mail address: austin.cooney@austin.utexas.edu (A.J.
http://dx.doi.org/10.1016/j.scr.2016.02.032
1873-5061/© 2016 University of Texas at Austin D
(http://creativecommons.org/licenses/by-nc-nd/4.0/).a b s t r a c ta r t i c l e i n f oArticle history:
Received 21 December 2015
Received in revised form 17 February 2016
Accepted 18 February 2016
Available online 23 February 2016Induced pluripotent stem (iPS) cells can efﬁciently differentiate into the three germ layers similar to those
formed by differentiated embryonic stem (ES) cells. This provides a new source of cells inwhich to establish pre-
clinical allogeneic transplantation models. Our iPS cells were generated from mouse embryonic ﬁbroblasts
(MEFs) transfected with the Yamanaka factors, the four transcription factors (Oct4, Sox2, Klf4 and c-Myc),
without antibiotic selection orMEF feeders. After the formation of embryoid bodies (EBs), iPS cells spontaneously
differentiated into Flk1-positive cardiac progenitors and cardiomyocytes expressing cardiac-speciﬁc markers
such as alpha sarcomeric actinin (α-actinin), cardiac alpha myosin heavy chain (α-MHC), cardiac troponin T
(cTnT), and connexin 43 (CX43), as well as cardiac transcription factors Nk2 homebox 5 (Nkx2.5) and gata bind-
ing protein 4 (gata4). The electrophysiological activity of iPS cell-derived cardiomyocytes (iPS-CMs) was detect-
ed in beating cell clusters with opticalmapping and RH237 a voltage-sensitive dye, and in single contracting cells
with patch-clamp technology. Incompletely differentiated iPS cells formed teratomas when transplanted into a
severe combined immunodeﬁciency (SCID)mousemodel ofmyocardial infarction. Our results show that somatic
cells can be reprogrammed into pluripotent stem cells, which in turn spontaneously differentiate into electro-
physiologically functional mature cardiomyocytes expressing cardiac-speciﬁc makers, and that these cells can
potentially be used to repair myocardial infarction (MI) in the future.
© 2016 University of Texas at Austin Dell Medical School. Published by Elsevier B.V. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Heart failure caused by the dysfunction or damage of cardiomyocytes
is a leading cause of death and disability (Roger, 2013). Dysfunctional or
damaged cardiomyocytes cannot be replaced because human postnatal
cardiomyocytes become terminally-differentiated after birth and
lose their ability to proliferate (Ellison et al., 2013). Other studies
have shown that the adult heart has limited capacity to regenerate
cardiomyocytes through cardiac stem cell (CSC) differentiation or
through proliferation of cardiomyocytes in vivo, although CSCs can easily
be induced to differentiate into cardiomyocytes in vitro (Tallini et al.,
2009; Miyamoto et al., 2010; Zaruba et al., 2010). Furthermore, there is
no evidence that stem cells derived from other sources, such as the
bone marrow, are able to give rise to contractile cardiac cells after trans-
plantation into the heart (Wen et al., 2012). The therapeutic effect of stem
cells is, thought to be,mediated by paracrinemechanisms, such as the re-
lease of cytokines and growth factors,which inhibit apoptosis andﬁbrosis
formation, enhance contractility, and activate endogenous regenerativeCooney).
ell Medical School. Published bymechanisms (Tang et al., 2004; Wang et al., 2008). Embryonic stem
(ES) cells, a type of pluripotent stem cell derived from early developing
embryos, can potentially differentiate into all cell types derived from
the three germ layers, including cardiac lineages (Caspi et al., 2007;
Martín et al., 2007; van Laake et al., 2007). However, several ethical and
practical issues limit the use of human ES cells and thus these cells are
not readily accessible as an autologous cell source (Nussbaum et al.,
2007). Current stem cell therapeutic approaches are still limited by the
availability of reliable cell sources.
The recent generation of iPS cells has brought new hope to the ﬁeld of
regenerativemedicine. Similar to ES cells, iPS cells are able to differentiate
into all cell types of the three primary germ layers, which offers a unique
approach for regenerative cell therapy (Takahashi and Yamanaka, 2006;
Takahashi et al., 2007; Yu et al., 2007). Especially, human iPS cell-
derived cardiomyocytes (iPS-CMs) show nodal-, atrial-, and ventricular-
like phenotypes of gene expression and electrophysiological properties
(van Laake et al., 2010; Xi et al., 2010; Germanguz et al., 2011) and are re-
sponsive to β-adrenergic stimulation (Germanguz et al., 2011; Zhang
et al., 2009). However, transplantation of undifferentiated iPS cells into
the heart can result in teratomas because of the embryonic characteristics
of the cells or possible activation of oncogenes (Nelson et al., 2009;WangElsevier B.V. This is an open access article under the CC BY-NC-ND license
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integrating methods bypass the risk of teratoma formation; engrafts
remainwithin the infarcted heart and result in improved cardiac function
after ischemic damage (Ahmed et al., 2011; Singla et al., 2011; Kawamura
et al., 2013;Martinez-Fernandez et al., 2009). However, the generation of
sufﬁcient functional iPS-CMs with high purity and maturity (Mauritz
et al., 2008; Gai et al., 2009; Kuzmenkin et al., 2009) remains challenging.
Here we describe the generation of iPS cells from mouse embryonic
MEFs using four transcription factors (Oct4, Sox2, Klf4 and C-myc),
without feeder cells or antibiotic selection. The cardiac markers, includ-
ing α-actinin, MHC, cTnT, CX43, Nkx2.5, and Gata4, were tested. The
electrophysiological action potentialwas veriﬁed bypatch-clamp in sin-
gle contracting cells, and recorded by optical mapping with RH237, a
voltage-sensitive dye, in iPS-CM clusters. These results show that
mature functional cardiomyocytes with cardiac-speciﬁc markers and
cardiomyocyte potential can be derived from somatic cells via cellular
reprogramming methodologies.
2. Materials and methods
All surgical operations related to mice in the experiments were
performed under anesthesia, and mice were sacriﬁced by euthanasia.
These experiments were approved by the Institutional Animal Care
and Use Committee (IACUC) of Baylor College of Medicine.
2.1. Generation of iPS cells
The original Yamanaka pMXs-based retroviral vectors encoding
Oct4, Sox2, Klf4, and C-myc (cat# 13366, 13367, 13370 and 13375,
Addgene) (Takahashi and Yamanaka, 2006) were introduced individu-
ally into each 10 cm plate with Plat-E cells with Fugene 6 transfection
reagent (cat# 11814443001, Roche) according to the manufacturer's
recommendations. After 24 h of transfection, virus-containing superna-
tants derived from these Plat-E cultures were ﬁltered through a 0.45 μm
cellulose acetate ﬁlter and supplemented with 4 μg/ml polybrene.
One day before infection, 8 × 105 MEF cells were seeded into 10 cm
0.1% gelatin-coated plates. MEF cells were then incubated with virus/
polybrene-containing supernatants overnight. MEFs were infected
twice. After 24 h of infection, the media were replaced with 10 ml
fresh ES cell media. The iPS cells were generated without antibiotic se-
lection (Meissner et al., 2007). Three weeks later, alkaline phosphatase
staining (cat# SK-5100, Vector Laboratories)was carried out to evaluate
reprogramming efﬁciency, and colonies were selected according to a
morphology characteristic of ES colonies (Meissner et al., 2007). To es-
tablish stable iPS cell lines, a single iPS colony was picked into one
well of a 24-well plate. The iPS colonies used in our experiments were
from lines in which the viral ectopic genes Oct4, Sox2, Klf4 and c-Myc
were shown to be silenced (Wang et al., 2013).
2.2. Differentiation of iPS cells into cardiomyocytes
Both iPS and ES cells were maintained on tissue culture dishes coat-
ed with 0.1% gelatin. Subsequently, cell colonies were dissociated into
single cell suspensions with 0.25% trypsin–EDTA (cat# 25200-056,
Invitrogen). To induce embryoid body (EB) formation, cells were
plated in Petri dishes containing differentiation medium composed of
Dulbecco's Modiﬁed Eagle's medium (DMEM) (Invitrogen), 15% fetal
bovine serum, 0.2 mmol/l L-glutamine, 0.1 mmol/l nonessential amino
acids, and 0.1 mmol/l β-mercaptoethanol. The cells aggregated sponta-
neously to from EBs. At day 5 of differentiation, 10 EBs per well were
seeded into a 0.1% gelatin-coated 6-well culture dish or 3 EBs per well
on a gelatin-coated 12-well culture dish (Nunc) for immunoﬂuores-
cence analyses. Differentiation medium was replaced every second to
third day. Starting on day 6 of differentiation (1 day after plating),
each EB outgrowth was examined daily for beating areas.2.3. Immunoﬂuorescence staining
The iPS cells and the cells at days 22–28 of iPS EB differentiation
were ﬁxed with paraformaldehyde, and stained following a standard
immunostaining procedure. Brieﬂy, cells were ﬁxed in 4% formaldehyde
solution in phosphate-buffered saline (PBS), permeated with 5% bovine
serum albumin (BSA) plus 0.1 Triton X100, and blocked with 5% BSA
plus 0.01% Tween 20. The primary and secondary antibodieswere dilut-
ed in blocking solution. The primary antibodies against mouse Nanog
(cat# ab80892, Abcam), Sox2 (cat# ab5603, Millipore), Oct4 (cat# sc-
5279, Santa Cruz), Connex43 (cat# C6219, Sigma),α-sarcomeric actinin
(cat# A7732, Sigma), MHC (ab15, Abcam), cTnT (ab8295, Abcam),
Laminin (cat# ab11575, Abcam), SM22 alpha (cat# ab14106, Abcam),
alpha smooth muscle Actin (cat# ab5694, Abcam), Calponin (cat#
ab46794, Abcam); GATA4 (cat# AF2606, R&D System), and NKx2.5
(cat# AF2444, R&D System) were used at a 1:200 dilution. Secondary
antibodies, Texas Red AfﬁniPure Donkey Anti-Mouse IgG (cat# 715-
075-150, Jackson ImmunoResearch), Texas Red AfﬁniPure Donkey
Anti-Goat IgG (H + L) (cat# 705-075-003, Jackson ImmunoResearch),
FITC AfﬁniPure Donkey Anti Rabbit IgG (H + L) (cat# 711-095-152,
Jackson ImmunoResearch), and Texas Red AfﬁniPure Donkey Anti-
Rabbit IgG (H + L) (cat# 711-075-152, Jackson ImmunoResearch)
were used at a 1:200 dilution.
2.4. Fluorescence-activated cell sorting (FACS)
Cells at day 4 or day 8 of EB differentiation were dispersed with
2mM EDTA in DMEM, stained with anti-Flk 1 antibody (1:200 dilution)
(cat# 555307, BD Pharmingen) as the primary antibody; and then
stained with goat anti-rat IgG-PE (sc-3740, Santa Cruz Biotechnology)
diluted 1:200 as secondary antibody. Flk1-positive cells were analyzed
with a Flow Cytometer BD LSRFortessa (BD Biosciences).
2.5. Preparation of the acute myocardial infarction (AMI)mousemodel and
transplantation of EB cells
The acute myocardial infarction (AMI) models were created by sur-
gically ligating the left anterior descending artery of 8-week-old SCID
C57/BL6 mice anesthetized with isoﬂurane (2%). The AMI model was
created within 2 min after ligation. The surface of the infarcted region
looked white, instead of red, and a surface electrocardiograph detected
dynamic changes in the T and the Qwaves.We injected 1 × 106 iPS cells
at day 5 of EB differentiation into the infarcted region right after the li-
gation in six mice. The six AMI mice were used as controls. The mice
were euthanized and the hearts were surgically excised at days 7 and
28 after AMI induction,ﬁxed in 4%paraformaldehyde, embedded in par-
afﬁn, sectioned, and stained. Cell survival, proliferation, differentiation,
and presence of teratomas were evaluated. The IACUC of Baylor College
of Medicine approved the experimental protocol.
2.6. Detection of action potentials of iPS-CMs by optical mapping
The electrophysiological activity of clusters of iPS-derived beating
cells was recorded by an optical mapping system using RH237 a
voltage-sensitive dye as previously described (Xi et al., 2013). Brieﬂy,
beating clusters (22–28 days after differentiation) were cultured in
35 mm dishes overnight, and then surface perfused at 37 °C with mod-
iﬁed Tyrode's solution containing 126 mmol/l NaCl, 5.4 mmol/l KCl,
0.8mmol/lMgCl2, 10mmol/l glucose, and 10mmol/l HEPES (pH 7.4 ad-
justed with 1 mol/l NaOH). After 5 min, the clusters were incubated
with the voltage-sensitive dye RH237 (1 μmol/l) for 5 min. The optical
signal was excited with custom-made LED and recorded with a high
frequency CCD camera (710 frames/s). The data was processed with
an algorithm on theMatlab platform and phasemaps were constructed
using a time-delay embedding method (Bray et al., 2001).
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Beating clusters were dissociated with 0.25% trypsin–EDTA and sin-
gle cell suspensions were plated onto 0.1% gelatin-coated glass cover-
slips and continuously cultured for 1–2 days. Spontaneously beating
individual iPS-CMs were selected for patch-clamp experiments. For ac-
tion potential recording, we used the perforated patch techniquewith a
pipette solution containing amphotericin B (240mg/l, Sigma, MO)with
a current-clamp mode of Axon multiclamp 700 A ampliﬁer and patch
clamp 10.0 software (Molecular Devices, CA). The pipette solution
used to record action potentials and K+ current contained 120 mmol/l
K-aspartate, 10 mmol/l Na2ATP, 2 mmol/l MgCl2, 10 mmol/l EGTA, and
10 mmol/l HEPES (pH 7.35 adjusted with 1 mol/l KOH). Cells were
perfused with Tyrode's solution during these experiments.
2.8. RNA isolation and analysis
Total RNAs were isolated from cell samples using TRizol reagent
(catalog# 15596018, Invitrogen). RNA samples were analyzed with re-
verse transcription (RT)-PCR or quantitative real-time polymerase
chain reaction (qRT-PCR) with SYBR green Q-PCR reagent (catalog#
208056, Qiagen) and gene speciﬁc PCR primers, as listed in Supplemen-
tal Table 1.
2.9. Statistical analysis
All data were obtained from triplicate experiments and presented as
mean± standard deviation (SD). Student's T-test was performed to de-
termine the differences among grouped data. * indicates no statistical
signiﬁcance with P ≥ 0.05; ** indicates statistical signiﬁcance with
P b 0.05.
3. Results
3.1. Differentiation of iPS cells into spontaneously contracting cells and
mesoderm progenitor cells in vitro
Mouse iPS cells were generated by viral introduction of the four
Yamanaka factors—Oct4, Sox2, c-Myc and Klf4—into mouse embryonic
ﬁbroblasts and then subsequently selecting morphologically ‘good’ iPS
colonies, generated without antibiotic selection or MEF feeders (Wang
et al., 2013). The selected iPS colonies were positive for endogenous
Oct4, Sox2, andNanog expressionusingﬂuorescently labeled antibodies
and stained for alkaline phosphatase (ALP) activity (Wang et al., 2013).
Exogenous viral expression of Oct4, Sox2, c-Myc, and Klf4 was silenced
in the iPS clone used in this experiment (Takahashi and Yamanaka,
2006). In addition the iPS cells were conﬁrmed to have the ability to
form EBs, and chimeras, and to be germ line competent (Takahashi
and Yamanaka, 2006; Wang et al., 2013). In order to induce the iPS
cells to differentiate into functional cardiomyocytes, the cells were dis-
sociated into a single cell suspension by trypsinization, after which they
spontaneously aggregated to form EBs in Petri dishes to which they do
not adhere. After 5 days, the iPS EBs were transferred to 0.1% gelatin-
coated tissue culture plates to which they adhered. Five to seven days
later, beating cells were observed in the cultures (Supplementary
Video 1); different colonies were beating at different frequencies,
which were distinguished by different motions (Fig. 1A and B).
Flk1 is a receptor for vascular endothelial growth factor A (VEGF-A),
that is expressed in early lateral mesodermal progenitor cells at the
primitive streak stage. Flk1-positive progenitor cells are multipotent;
they can differentiate into endothelial cells, smooth muscle cells, and
cardiomyocytes (Misfeldt et al., 2009; Kattman et al., 2006), which
indicates that they could potentially be used to establish more useful
therapeutic approaches for human cardiovascular diseases such as is-
chemia or MI. In order to validate the ability of iPS cells to differentiate
into cardiac progenitor cells, we analyzed Flk1 expression during thedifferentiation process using FACS. The results show that 11.6% of iPS
EB cells differentiated into Flk1-positive cells at day 4 of differentiation
(Fig. 1C). By day 8, 17.3% of iPS EB cells had differentiated into
Flk1-positive cells (Fig. 1D). While, 2.7% of ES cells at days 4 (Fig. 1E)
and 5.4% at day 8 (Fig. 1F) were Flk1-positive. These data demonstrate
that iPS cells can differentiate into mesodermal progenitor-Flk-1
positive cells, and thus had the potential to differentiate into
cardiomyocytes and endothelial, and vascular smooth muscle lineages
(Kattman et al., 2006).
3.2. iPS cell-derived differentiated cells express cardiac-speciﬁc markers
The expression of cardiac-speciﬁc markers is a key feature of
cardiomyocytes derived from iPS cells. At days 22–28 of differentiation
some iPS-derived cells expressed the cardiac transcription factors
Nkx2.5 (Fig. 2A–C) and gata4 (Fig. 2D–F) in the nucleus conﬁrmed by
immunostaining. This suggests that iPS cells differentiated spontane-
ously toward cardiac lineages.
To evaluate the expression of myoﬁlament proteins and the sarco-
meric organization in iPS-CMs, we performed immunostaining of differ-
entiated EB cells at days 22–28 with antibodies for cardiac-speciﬁc
markers. The MHC (Fig. 3A–C), α-actinin (Fig. 3D–F), and cTnT
(Fig. 3G–I) markers were expressed in the cytoplasm and sarcomere
of cells, indicating that those sarcomere proteins were well organized.
CX43, an important component of gap junctions in ventricular cells,
was expressed in the cell membranes between the cells in a cluster
(Fig. 4A–C), and was expressed on sites where the membranes made
contact with other cells (Fig. 4D–F). CX43was also detected in the cyto-
plasm of single cells (Fig. 4G–I).
Other markers related to cardiac cells were also tested. Calponin, a
calcium binding protein that is indispensable for muscle contraction,
was also expressed in iPS-derived cells (Fig. 5A–C). Moreover, the
smooth muscle cell markers SM22 (Fig. 5D–F) and SMA (Fig. 5G–I)
were expressed in differentiated iPS cells too. Laminin was also found
in differentiated iPS cells (Fig. 5J–L). These results show that iPS-CMs
express mature cardiac protein markers.
3.3. iPS-CMs possess electrophysiological activity
The important feature of cardiac myocytes is their electrophysiolog-
ical activity. The action potentials of iPS-CMs were determined after the
iPS cells were induced to spontaneously differentiate into contracting
cells. We recorded their electrophysiological activity with an optical
mapping system for action potentials using the voltage-sensitive
dye RH237 (Fig. 6A and Supplementary Video 2). We found that cells
were electrophysiologically active beating at a rate of 360 bpm. The
electrical waves propagated throughout the beating area. This indicates
that iPS cells can differentiate into electrophysiologically functional
cardiomyocytes.
To further test the action potentials of single beating cells, beating
clusters were trypsinized to obtain a single cell suspension and subse-
quently re-plated on 0.1% gelatin coated-cover slides, and then tested
by patch-clamping of single beating cells. The resulting maps from the
patch-clamp studies showed that the pattern of action potentials was
similar to that of cardiomyocytes (Fig. 6B).
3.4. Transplantation of incompletely differentiated iPS cells results in
teratomas in an AMI mouse model
To validate the safety of transplanting incompletely differentiated
iPS cells, we created a mouse AMI model by surgically ligating the left
anterior descending coronary arteries of SCID C57/BL6 mice. We dis-
persed iPS EB cells at day 5 of differentiation into a single cell suspension
and 1× 106 cells in PBSwere transplanted into a broad zone of damaged
tissue within the hearts of female AMI SCID mice (n = 3) after AMI
models were made. The hearts were collected at day 7 or 28 after
Fig. 1. iPS cells differentiate into Flk1-positive beating cells with diverse rates. (A) Two beating clusters (A1 and A2) in the iPS-derived EB cultures. (B) The colors trace the beating
frequency of A1 cluster (green and blue) and A2 cluster (red and yellow) corresponding to the clusters in A. (C) FACS analysis of Flk1-positive cells on day 4 of iPS EB differentiation.
(D) FACS analysis of Flk1-positive cells on day 8 of iPS EB differentiation. (E) FACS analysis of Flk1-positive cells on day 4 of ES EB differentiation. (F) FACS analysis of Flk1-positive cells
on day 8 of ES EB differentiation.
525H. Wang et al. / Stem Cell Research 16 (2016) 522–530transplantation. Hematoxylin and eosin (HE) staining results showed
that the injected cells were present around the site of injection after
7 days of transplantation. The proliferating cells showed teratomacharacteristics (Fig. 7A and B). Twenty-eight days later, a number
of proliferating cells were found in the site where the original
cardiomyocytes had died and formed a teratoma (Fig. 7C and D). Thus,
Fig. 2. Expression of transcription factors related to cardiac development at days 22–28 of iPS EB differentiation. Immunostaining of: (A) Nkx2.5 (red); (B) DAPI (blue) and (C) merge of
Nkx2.5 (red) and DAPI (blue). Immunostaining of: (D) Gata4 (red); (E) DAPI (blue) and merge of gata4 (red); and (F) DAPI (blue). Bar scale = 20 μm.
526 H. Wang et al. / Stem Cell Research 16 (2016) 522–530incompletely differentiated iPS cells transplanted into damaged areas of
the heart can survive and grow, but they present the risk of becoming a
tumor.
4. Discussion
ES cells have been reported to improve the function of damaged
hearts by differentiating into cardiac lineages and enhancing neovascu-
larization via the release of speciﬁc factors (Fatma et al., 2010).
However, the results were more diverse among different iPS cell lines
than ES cells, despite the fact that iPS cells closely resemble ES cells in
morphology and developmental potential (Takahashi and Yamanaka,
2006; Wang et al., 2013). To further establish stable iPS cell lines, weFig. 3. Expression of cardiac-speciﬁc markers at days 22–28 of iPS EB differentiation. Immunos
Immunostaining of: (D) α-actinin (red); (E) DAPI (blue) and (F) merge of α-actinin (red) a
(red); (I) and DAPI (blue). Bar scale = 30 μm.selected iPS cells whose exogenously transfected Oct3/4, Sox2, Klf4,
and c-Myc were silenced; these cells were conﬁrmed to have pluripo-
tent properties in vitro and in vivo, including germ line transmission ca-
pabilities (Wang et al., 2013; Deng et al., 2011). Our iPS cells generated
from ﬁbroblast cells shared similar undifferentiated characteristics with
ES cells (Takahashi and Yamanaka, 2006; Evans and Kaufman, 1981).
Moreover, our iPS cells were able to spontaneously differentiate into
mature contractile cardiomyocytes expressing speciﬁc cardiac markers,
such asα-actinin,MHC, and cTnT, and having awell-organized distribu-
tion and indistinguishable sarcomeric organization. This suggests that
iPS cells are capable of differentiating into mature cardiomyocytes. Al-
though the iPS cells have the capacity to spontaneously differentiate
into CMs, the efﬁciency is low. Thus, induction factors, such as cardiactaining of: (A) MHC (red); (B) DAPI (blue) and (C) merge of MHC (red) and DAPI (blue).
nd DAPI (blue). Immunostaining of: (G) cTnT (red); (H) DAPI (blue) and merge of cTnT
Fig. 4.Distribution of gap junction protein CX 43 at days 22–28 of iPS EB differentiation. Cluster immunostaining of: (A) CX43 (red); (B) DAPI (blue) and (C)merge of CX43 (red) andDAPI
(blue). Two-cell immunostaining of: (D) CX43 (red); (E) DAPI (blue) and (F) merge of CX43 (red) and DAPI (blue). Single cell immunostaining of: (G) CX43 (red); (H) DAPI (blue) and
(I) merge of CX43 (red) and DAPI (blue). Bar scale = 10 μm.
Fig. 5. Expression of other genes during days 22–28 of iPS EBdifferentiation. Immunostaining of: (A) Calponin (green); (B) DAPI (blue) and (C)merge of Calponin (green) andDAPI (blue).
Immunostaining of: (D) SM22 (red); (E) DAPI (blue) and (F) merge of SM22 (red) and DAPI (blue). Immunostaining of: (G) SMA (green); (H) DAPI (blue) and (I) merge of SMA (green)
and DAPI (blue). Immunostaining of: (J) Laminin (green); (K) DAPI (blue) and (L) merge of Laminin (green) and DAPI (blue). Bar scale = 10 μm.
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Fig. 6. Evaluation of electrophysiological activity. (A) Recorded by optical mapping using the voltage-sensitive dye RH237. Intervals between pictures = 28 mS. Beat rate = 360 bpm. A
(a–k), Propagation within the beating cluster. l, Phase map. (B) Electrophysiological potential of single beating cells recorded using patch-clamping.
528 H. Wang et al. / Stem Cell Research 16 (2016) 522–530speciﬁc transcription factors, should be included in the process to
improve the efﬁciency of cardiac differentiation.
Gap junctions play an important role in intercellular impulse propa-
gation within the myocardium. Cardiac gap junctions are composed of
proteins called connexins (Cxs). Cxs form low resistance channels that
enable electrical coupling of adjacentmyocytes and intercellular electri-
cal communication. These Cxs are distributed in speciﬁc cells, exhibit di-
verse properties, and are regulated by different gating mechanisms.
There are as many as three major isoforms of Cxs in the heart.
Studies have shown that a homomeric composition of gap junctions,
e.g., Cx40/Cx40, and Cx43/Cx43, is required for efﬁcient communication
between cells in exogenous expression systems. CX43 is the only Cx
known to be expressed in the adult workingmyocardium of the ventri-
cle (van Kempen et al., 1991). Alterations in the localization, expression
level, and nature of Cx43 cause abnormal electrical conduction,
leading to arrhythmias (Poelzing and Rosenbaum, 2004). Transplanta-
tion of non-Cx43-expressing cells would promote arrhythmia in the
area of the myocardial infarction (Solomon et al., 2005; Henkel et al.,
2006). Therefore, engraftment of Cx43-expressing myocytes canpotentially reduce life-threatening post-infarct arrhythmias through
the augmentation of intercellular coupling in a cardiac cell-based
therapy (Roell et al., 2007). In the present study, we have shown that
Cx43 is only expressed on the membranes of adjacent iPSC-CMs,
which need communication or material exchange. However, further
functional studies are warranted to determine functional gap junction
formation.
Electrophysiological activity is an important feature and a basic func-
tion of cardiomyocytes. It ensures that cardiomyocytes contract syn-
chronously in response to stimulation from the sinoatrial node. We
used an optical mapping system to test the electrophysiological activity
of beating clusters and patch-clamping to test this activity in single
beating single cells. The results showed that both spontaneously beating
clusters of iPS-CM and single iPS-CM cells ﬁre action potentials. The rate
of beating of iPS-CMs was similar to that of mouse cardiomyocytes.
This indicates that iPS-CMs possess not only the markers of mature
cardiomyocytes but also electrophysiological function, and would be
prone to couple or synchronize with host cells, and potentially avoid
arrhythmia after transplantation into the myocardium.
Fig. 7. HE staining of AMI hearts 1 and 4 weeks after transplantation of iPS cells derived from cells at day 5 of EB differentiation. (A and B) H&E staining of heart tissue one week after
transplantation of iPS-derived EB cells into the AMI. (C and D) H&E staining of heart tissue four weeks after transplantation of iPS-derived EB cells into the AMI. Dotted lines separate
healthy and ischemic areas. Scale bar = 100 μM.
529H. Wang et al. / Stem Cell Research 16 (2016) 522–530We also determined the safety of transplanting incompletely
differentiated iPS cells. It has been demonstrated that iPS-CMs are safe
after transplantation into the heart, but their proliferation is limited
(Nelson et al., 2009). Therefore, the selection of adequate time points
during differentiation of iPS cells is critical. Flk1-positive cells were se-
lected as cardiac progenitors as they possess the capability to differenti-
ate into cardiac lineages (Kattman et al., 2006). In the present study, EBs
of iPS cells at days 4 to 8 of differentiation showed a signiﬁcant increase
in Flk1-positive cells. However, unpuriﬁed Flk1-positive cells formed
teratomas after injection into the hearts of our AMI mouse models;
therefore it is unsafe to inject incompletely differentiated iPS cells
into the heart. Expression of the Yamanaka factors was silenced in the
iPS cells and was not re-activated during the formation of iPSC-CMs
(Supplementary Fig. 1), so engrafts derived from more mature cells
seemed to be safe (Yan et al., 2011). However, this raised another
important issue of whether iPS cell-derived cardiac myocytes would
couple with host cells successfully. Engrafts will promote arrhythmia
if injected cells cannot couple or synchronize with host cells (Liao
et al., 2010).
5. Conclusion
The present study shows that iPS-CMs express cardiac speciﬁc
markers, express membrane connexin-43, and display cardiac electro-
physiological activity. These results indicate that iPS cells might
be a promising cell source for the generation of patient-speciﬁc
cardiomyocytes (Park et al., 2008; Soldner et al., 2009), even for patients
with severe heart disease (Carvajal-Vergara et al., 2010; Han et al.,
2014), because the cells can be made available in unlimited amountsand are capable of cardiomyocyte generation. However, further studies
are warranted to determine the right subgroup of iPS-CMs at a right
stage of differentiation to clarify safety issues.
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